FibroBiologics, Historical Income Statement
| FBLG Stock | 2.56 0.09 3.64% |
Historical analysis of FibroBiologics, Common income statement accounts such as Other Operating Expenses of 9.3 M or Research Development of 1.3 M can show how well FibroBiologics, Common Stock performed in making a profits. Evaluating FibroBiologics, Common income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of FibroBiologics, Common's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining FibroBiologics, Common latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether FibroBiologics, Common is a good buy for the upcoming year.
FibroBiologics, |
About FibroBiologics, Income Statement Analysis
FibroBiologics, Common Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to FibroBiologics, Common shareholders. The income statement also shows FibroBiologics, investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
FibroBiologics, Common Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of FibroBiologics, Common. It is also known as FibroBiologics, Common overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Total Revenue
Total revenue comprises all receipts FibroBiologics, Common generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Most accounts from FibroBiologics, Common's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into FibroBiologics, Common current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in FibroBiologics, Common Stock. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. At this time, FibroBiologics, Common's Other Operating Expenses is most likely to increase significantly in the upcoming years. The FibroBiologics, Common's current Total Operating Expenses is estimated to increase to about 9.3 M, while Selling General Administrative is projected to decrease to roughly 2.9 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 1.6M | 4.4M | 8.9M | 9.3M | Research Development | 521K | 1.1M | 2.4M | 1.3M |
FibroBiologics, Common income statement Correlations
Click cells to compare fundamentals
FibroBiologics, Common Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Currently Active Assets on Macroaxis
When determining whether FibroBiologics, Common is a strong investment it is important to analyze FibroBiologics, Common's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact FibroBiologics, Common's future performance. For an informed investment choice regarding FibroBiologics, Stock, refer to the following important reports:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in FibroBiologics, Common Stock. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of FibroBiologics, Common. If investors know FibroBiologics, will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about FibroBiologics, Common listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.59) | Return On Assets (0.62) | Return On Equity (4.34) |
The market value of FibroBiologics, Common is measured differently than its book value, which is the value of FibroBiologics, that is recorded on the company's balance sheet. Investors also form their own opinion of FibroBiologics, Common's value that differs from its market value or its book value, called intrinsic value, which is FibroBiologics, Common's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because FibroBiologics, Common's market value can be influenced by many factors that don't directly affect FibroBiologics, Common's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between FibroBiologics, Common's value and its price as these two are different measures arrived at by different means. Investors typically determine if FibroBiologics, Common is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, FibroBiologics, Common's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.